



Published in final edited form as:

FEBS Lett. 2019 April ; 593(7): 680–696. doi:10.1002/1873-3468.13348.

The impact of Megf10/Drpr gain-of-function on muscle development in *Drosophila*

Isabelle Draper¹, Madhurima Saha², Hannah Stonebreaker³, Robert N. Salomon⁴, Bahar Matin¹, and Peter B. Kang^{2,3,5,6}

¹Department of Medicine, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA 02111, USA

²Department of Pediatrics, Division of Pediatric Neurology, University of Florida College of Medicine, Gainesville, FL 32610, USA

³Department of Neurology, Boston Children's Hospital, Boston, MA 02115, USA

⁴Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA 02111, USA

⁵Department of Molecular Genetics and Microbiology and Department of Neurology, University of Florida College of Medicine, Gainesville, FL 32610, USA

⁶Genetics Institute and Myology Institute, University of Florida, Gainesville, FL 32610, USA

Abstract

Recessive mutations in multiple EGF-like domains 10 (MEGF10) underlie a rare congenital muscle disease known as MEGF10 myopathy. MEGF10 and its *Drosophila* homolog Draper (Drpr) are transmembrane receptors expressed in muscle and glia. Drpr deficiency is known to result in muscle abnormalities in flies. In the current study, flies that ubiquitously overexpress Drpr, or mouse Megf10, display developmental arrest. The phenotype is reproduced with overexpression in muscle, but not other tissues, and with overexpression during intermediate stages of myogenesis, but not in myoblasts. We find that tubular muscle subtypes are particularly sensitive to Megf10/Drpr overexpression. Complementary genetic analyses show that Megf10/Drpr and Notch may interact to regulate myogenesis. Our findings provide a basis for investigating MEGF10 in muscle development using *Drosophila*.

Keywords

Drosophila; Drpr; Megf10; Myogenesis; MEGF10 Myopathy

Introduction

MEGF10 myopathy or EMARDD (Early onset Myopathy, Areflexia, Respiratory Distress and Dysphagia) is a rare human congenital muscle disease caused by mutations in multiple

EGF-like domains 10 (MEGF10) [1–3]. This single transmembrane receptor is expressed in skeletal muscles, the retina and in CNS glial cells, and is conserved through evolution. The *Drosophila melanogaster* (i.e., fruit fly) homolog of human MEGF10 is Draper (Drpr). Conservation of MEGF10 from insect to human, together with the versatility of fly genetics, and the identification in flies of adult muscle precursor cells (AMPs) that resemble satellite cells of higher organisms [4, 5] make *Drosophila* a useful model organism to investigate mechanisms underlying the pathogenesis of human MEGF10 myopathy. In addition to overlap in structure, similarity in reported function between human MEGF10 and fly Drpr has been described (e.g., regulation of glial engulfment of degenerating/apoptotic neurons, synapse sculpting during development) [6–17]. More recently, studies have revealed an important role for Drpr in the adult brain after axonal injury [18] as well as during aging [19]. Many gaps remain however in our understanding of the molecular functions of MEGF10/Drpr in muscle cells, and the potential efficacy and tolerance for restoration of MEGF10 in disease models has not been explored in that context. We have previously shown that loss-of-function mutations in Drpr lead to muscle alterations that recapitulate important features of the human disease [20]. We have generated and characterized a complementary model of MEGF10/Drpr gain-of-function in *Drosophila* muscle. Our MEGF10 loss of function and gain of function *Drosophila* models enable us to begin dissecting the conserved functional pathways regulated by this protein in muscle cells. Using our fly models, we have initiated genetic studies focused on interactions with the Notch pathway, which is an important regulator of muscle cell proliferation and differentiation.

Materials and Methods

Drosophila stocks and culture

The *UAS-drpr-I*, *UAS-drpr-II* and *UAS-drpr-III* lines [8, 9], *UAS-megf10*, and *drpr*⁵ mutant fly line (genotype: *w*⁻; *sp/CyO*; *drpr* /*TM6, sb, Tb, e*; where *w*⁻; *sp/CyO*; *drpr* 5/*drpr* 5 null are adult viable [12]), were generously provided by Mary Logan (Oregon Health Sciences University, Portland, OR, USA) and Marc Freeman (Vollum Institute, Oregon Health Sciences University, Portland, OR, USA). The genetic background strain *w*¹¹¹⁸ (*w* allele FBal0018186) and *repo-Gal4* driver line (expression in glia) were donated by Mary Roberts (F. Rob Jackson laboratory, Tufts University School of Medicine, Boston, MA). The Gal4 driver lines listed in Table 1 were purchased from the Bloomington *Drosophila* Stock Center (Indiana University, Bloomington, IN). The *TinC-Gal4* driver line (expression in the heart) was donated by Dr. Matthew J. Wolf (Duke University, Durham, NC). All strains were raised at 25°C in a 12 h light/12 h dark cycle on standard *Drosophila* media. To generate flies that overexpress *Mus musculus* Megf10, or *Drosophila* Drpr, transgenics carrying the corresponding *UAS-cDNA* transgene were crossed with Gal4 driver flies [21] at 29°C, 25°C, or 18°C (the strength of the *Gal4/UAS* system is temperature sensitive, and more efficient at higher temperatures). For each Gal4 driver assessed, the corresponding genetic cross was made at least twice; the number of adult progeny observed in each cross range from 10 to 120 flies.

Assessment of transcript levels

RT-PCR was used to assess the transcription level of the *Mus musculus Megf10* and *Drosophila Act5C* (housekeeping) genes. For *Drosophila* that express mouse Megf10 ubiquitously (i.e., *Act5C-Gal4/UAS-Megf10* flies), and corresponding controls (i.e., (i) *UAS-Megf10* transgene bearing flies, and (ii) *w¹¹¹⁸* genetic background flies), a pool of two male and three female (5-day-old) adult flies were used. Of note, a large number of Megf10 expressing flies die before reaching the adult stage. We thus used the rare Megf10 expressing mutant escapers, regardless of gender, (and a matching number of males/females control flies). RNA was extracted with the RNA STAT-60 (Tel-Test, Inc., Friendswood, TX) following the manufacturer's recommendations. DNA contamination was removed prior to the reverse transcription using a DNA-free kit (Ambion). Complementary DNA was generated using a Superscript First-Strand kit (Life Technologies) following the manufacturer's recommendations. The conditions for RT included cycles of 25°C × 10 min, 42°C × 20 min, and 99°C × 5 min. Alternatively, genomic DNA was isolated from pooled adult male *UAS-Megf10* transgene-bearing flies using the QIAamo DNA Micro Kit (Qiagen), following the manufacturers' recommendations. PCR amplification was performed using the following protocol: pre-incubation at 94°C × 10 min, followed by 35 cycles of amplification: 94°C × 30 sec, 60°C × 30 sec, and 72°C × 1 min. The reaction was completed with a ten-minute incubation at 72°C. Primers were synthesized at the Tufts University Molecular Core (Tufts University, Boston, MA). All primers were designed specifically for cDNA, (Table 1, of note, transgenic flies that express mouse Megf10 carry the corresponding cDNA transgene). The PCR reactions were analyzed on an agarose gel, and PCR band intensity was quantified using Image J software (NIH). Transcript levels were expressed as a ratio of the control (housekeeping) gene *Actin5C*. The primer pair sequences are: *Act5C* forward, 5'-CAGCCAGCAGTCGTCTAATCC-3';

Act5C reverse, 5'-CGACAACCAGAGCAGCAACTT-3';

Megf10_1 forward, 5'-CTGCCGATTCTATCAGATC-3';

Megf10_1 reverse 5'-GCTCACTGTAGGTTGACTT-3'

Megf10_2 forward 5'-GTTGTTACCTGGGTACTG-3'

Megf10_2 reverse 5'-AGAGCAGTCAGTCCCTTTGA-3'

Statistical analysis

Statistical analysis was performed using GraphPad Prism, using paired t test, or two-way ANOVA (GraphPad Software, Inc., CA).

Histological analysis

Histological analyses were performed in the Department of Pathology and Laboratory Medicine, Tufts Medical Center. Two day-old *Wg-Gal4>UAS-dpr III* mutant *Drosophila* (that escaped lethality) were immersed in Telly's fixative for seven days, embedded in paraffin, and sectioned at 5 um using standard techniques. All sections were stained with hematoxylin and eosin, then examined using standard bright-field light microscopy. All

images were reviewed by one of the authors (R.N.S.), a pathologist with extensive experience with *Drosophila* histology and histopathology.

Results

Flies that overexpress mouse *Megf10* or fly *drpr* become arrested during development at the pupal/pharate adult stage.

Ubiquitous overexpression of Drpr isoforms I, II, III and mouse *Megf10* in the *w¹¹¹⁸* wildtype fly background each leads to a nearly universal failure to eclose (Fig. 1), suggesting that the motif responsible for the lethality is to be found in all isoforms of Drpr, including the shortest one, Drpr-III. The few “escapers” (from progeny generated at 18°C, under minimal GAL4 activity [22]), were found to have structural abnormalities in the appendages (i.e., legs and wings). Strikingly the observed leg abnormalities, including darkened tibia/tarsus junctions and absent tarsal segments, are reminiscent of those seen in Drpr-deficient mutant flies (Supplementary Fig. 1). Molecular analysis confirmed the presence of the mouse *Megf10* transgene in the *UAS-Megf10* mutant flies (a gift from Mary Logan), as well as of *Megf10* RNA in the double *Gal4/UAS* transgenic escaper flies that express *Megf10* in the entire organism (Supplementary Fig. 1, gDNA and cDNA analysis, respectively). The *UAS-Drpr I*, *UAS-Drpr II* and *UAS-Drpr III* lines (a gift from Marc Freeman), were previously characterized [9]. By using the *P{Act5C-GAL4}17bFO1* ubiquitous Gal4 driver (stock # 3954, Bloomington *Drosophila* stock center), it is possible to distinguish morphological differences between the experimental progeny that express the *Megf10* (or *drpr*) transgene, from control siblings that carry the transgene but do not express it. The latter carry a balancer third chromosome tagged with the dominant marker “Tubby” (*Tb*), which confers a shorter and thicker body size to the organisms, thus enabling easy quantification of experimental versus control flies throughout development (including the L1, L2, L3 larval, early and late pupal, and adult stages) (Fig. 2). We observed that flies that overexpress *Megf10* or Drpr develop normally until metamorphosis then become arrested, while control siblings proceed to the adult stage (Fig. 2). Many *Megf10*-overexpressing flies reach the dark pupae/pharate adult stage where they die (Fig. 2). Similar results are obtained with Drpr I-, and Drpr III- overexpression, while Drpr II-overexpressing flies die as light pupae (data not shown). The number of experimental pupae is not significantly different from that of control sibling pupae (*Tb*) that develop simultaneously in the same vial (Fig. 2). Consistent with these findings, overexpression of *Megf10/Drpr* in the muscles of the embryo and larva (using the *c142-Gal4* driver) does not result in premature death (i.e., the expected number of flies emerge). These results provide a basis on which to further understand the outcome of genetic analyses using a range of tissue-specific Gal4 drivers (Table 1). While selected drivers may be active throughout *Drosophila* development, results with the ubiquitous driver indicate that high levels of *Megf10/Drpr* are tolerated at early stages (i.e., embryo, larvae) of development but are deleterious at later stages (i.e., pupal/pharate adult).

Overexpression of *Megf10/Drpr* is poorly tolerated in developing muscle, but benign in other tissues.

The lethality phenotype is reproduced with overexpression of mouse *Megf10*, Drpr-I or Drpr-II in muscle, using the *How-Gal4* driver. *How-Gal4* also drives tendon expression,

however overexpressing Megf10 using the tendon-specific stripe (*sr*)-*Gal4* driver results in viable progeny (tendon overexpression of Megf10 thus does not cause the observed lethality). Similarly, targeted expression of Megf10/Drpr to the heart, glial cells, neurons, motor neurons, intestinal tract/malpighian tubules and fat body with corresponding drivers is well-tolerated (Table 1 and Fig. 3).

Drosophila are sensitive to Megf10/Drpr overexpression at a later timepoint in muscle development compared to Megf10/Drpr deficiency.

Specific Gal4 drivers were used to overexpress Megf10, Drpr-I, Drpr II or Drpr-III at different stages of myogenesis. *Drpr* is highly expressed in the adult muscle precursor (AMP)-like DmD8 cells (modENCODE Cell Lines RNA-Seq, <http://flybase.org/reports/FBgn0027594.html>), that express the transcription factor twist [23]. Targeted Megf10/Drpr overexpression to the AMPs/muscle precursor cells (using the *twist-Gal4* driver), as well as to muscle progenitor and founder cells (using the *kirre-Gal4* driver), is well tolerated. Targeted Megf10/Drpr expression to terminally differentiated muscle fibers (using the myosin heavy chain (*Mhc*)-*Gal4* driver) also result in viable progeny. Consistent with the latter observation, no deleterious effect is observed when Megf10/Drpr was expressed in the mature muscles of the adult fly, using the *DJ757* and *DJ667 Gal4* drivers (Table1). In contrast, lethality is observed when using the *Mef2-Gal4* (*Mef2* induces differentiation) and *apterous-Gal4* (*apterous* is a muscle identity gene) drivers (Table 1 and Fig. 4). These results indicate that Megf10/Drpr overexpression is harmful at specific stages of myogenesis that occur later than the stage that is sensitive to Megf10/Drpr deficiency [20].

The detrimental effect of Megf10/Drpr overexpression is muscle subtype selective.

Comparative analysis of the outcomes of genetic crosses using the *apterous-Gal4*, *cut-Gal4* and *vestigial-Gal4* drivers reveals differential sensitivities of various developing muscles to increased expression of Megf10/Drpr. While crosses established with either *apterous-Gal4* or *cut-Gal4* lead to lethality in the experimental progeny, crosses with *vestigial-Gal4* result in the generation of viable adults (Table 1, Fig. 5). Intriguingly, in cut-positive cells Megf10 expression results in more severe effect than that induced by its fly counterparts, while the opposite is seen in apterous-positive cells. We cannot exclude that the subtle functional differences observed when the mouse versus the fly ortholog is expressed *in vivo* result from interspecies sequence/ domain variation, e.g., the length of the extracellular domain (857 versus 800 amino acids, respectively). Apterous (*ap*) and cut (*ct*) promote the development of tubular muscles that compose the direct flight muscles (DFMs) and jump/leg muscles, while vestigial (*vg*) positive fibers develop into the fibrillar indirect flight muscles (IFMs) (Fig. 5).

Sequence alignment of Drosophila and mammalian MEGF10 homologs highlights conservation in domains characteristic of Notch ligands, including a DOS motif found in the longer protein isoforms.

Drpr is the *Drosophila* homolog of human MEGF10, MEGF11, and MEGF12 (the last is also known as Jedi). Sequence alignment (CLUSTAL 2.1, Fig. 6) of Drpr-I/Drpr-PB (1031 aa, accession number NP_728660.2), Drpr-II/Drpr-PA (594 aa, accession number NP_477450.1), Drpr-III/Drpr-PC (528 aa, accession number NP_001246549.1), Mus

musculus Megf10 protein (1147 aa, accession number AAH75647.1) and *Mus musculus* Megf12/Jedi protein (1034 aa, accession number AF444274.1) revealed a high degree of conservation in the extracellular EMI domain (N-terminus), and in the Delta/Serrate/LAG-2 (DSL)-like domain that is found in many Notch ligands [24] (Fig. 6), as well as in four EGF-like/laminin-like domains close to the transmembrane region of the protein. Of note, a Delta and OMS-11 (DOS)-like motif highly reminiscent of the DOS motif displayed by multiple canonical Notch ligands [25] is found in the longest MEGF family members (i.e., Drpr-I, Megf10 and Jedi) but not in the shorter Drpr-II and Drpr-III (Fig. 6). Intracellularly, the NPXY motif (Fig. 1) postulated to bind the phosphotyrosine binding adapter ced-6 [9, 26] is conserved, as well as other downstream tyrosine residues (at the same position as or adjacent to Megf10 p.Y1002, p.Y1030 and p.Y1048, not shown) suggesting that these residues and their phosphorylation status may influence the observed overexpression-induced phenotype. We postulate that each of the conserved motifs plays an important role in mediating the function of this family of receptors.

Overexpression of Drpr under the control of the Serrate-Gal4 driver leads to a wing vein phenotype reminiscent of that obtained with Notch deficiency.

Targeting increased expression of Drpr in selected wing cells that express the Notch ligand Serrate (using the *Serrate-Gal4* driver) results in a split vein (extra-branching) phenotype at the wing margin (*SerG4>Drpr*, Fig. 7A-C), similar to that seen in flies with decreased Notch signaling activity [27]. The phenotype is 100% penetrant when overexpressing the short Drpr-II and Drpr-III isoforms, and moderately penetrant (~50%) when overexpressing the longer Drpr-I protein. The wing vein phenotype is also seen in Drpr-III overexpressing progeny generated with the *c179-Gal4* driver which targets, among other tissues, wing imaginal disc cells [28] (Fig. 7B). Notably, expressing Drpr-II in Serrate positive cells leads to exacerbation of the wing vein phenotype, and corresponding flies display an abnormal “held out wing” phenotype (i.e., the wings are held at a 45°–90° angle from the body, Fig. 7C) that is not observed with Megf10, Drpr-I or Drpr-III (data not shown). Of note, this phenotype is reminiscent of that seen in *DWnt-2* mutant flies. *DWnt-2* activity is essential during pupation for proper DFM development [29]. In addition, *SerG4>Drpr II* flies display markedly reduced locomotor activity versus corresponding controls that do not express the Drpr-II transgene (Fig. 7D, Supplementary video).

Overexpression of Megf10/Drpr in Notch and Wingless positive cells leads to lethality. Severe muscle defects are seen in selected mutant flies that survive.

Increased expression of Drpr-I, Drpr-II, Drpr-III or Megf10 in Notch positive cells of the wing disc results death of the flies at the dark pupal/pharate adult stage (Fig. 7A and 7E). In addition, increased expression of Drpr-II in Wingless (Wg)-positive cells also leads to developmental arrest at the dark pupal/pharate adult stage (Fig. 7A). Although some progeny that overexpress Megf10 or the other Drpr isoforms (i.e., Drpr-I, Drpr-III) in Wg cells can escape lethality, these flies are short-lived (data not shown). Notably, H&E staining of tissues from *wgG4>Drpr-III* adult flies that escape lethality show clear abnormalities in the tubular fibers that comprise the jump muscle, but not in the fibrillar fibers of the indirect flight muscles (Fig. 8, Supplementary Fig. 2).

Discussion

The current studies suggest that the mechanisms underlying Megf10/Drpr overexpression-induced damaging effects in *Drosophila* are related to somatic muscle, as only ubiquitous and muscle-specific overexpression led to lethality, whereas overexpression in multiple other tissues (including the tendons, heart, glia, neurons) was tolerated. It is well-established that two distinct waves of myogenesis produce the embryonic/larval musculature and adult musculature in *Drosophila* [30]. Our observation that Megf10/Drpr overexpressing flies develop seemingly normally until the pupal/pharate adult stages, where they die, suggest that increased levels of these proteins do not perturb embryonic/larval myogenesis, but are detrimental to adult myogenesis. Furthermore, overexpression of mouse Megf10 and the fly isoforms Drpr-I, Drpr-II and Drpr-III each leads to arrested fly development. A region common to all three Drpr isoforms and mouse Megf10 likely promotes the interactions that trigger the lethal phenotype.

Candidate regions include the N terminus of the protein (signal peptide, EMI and DSL motifs), the four distal EGF-like and transmembrane domains, and limited intracellular sequences including the NPXY signal motif (known to mediate the internalization of membrane proteins [31]) (Fig. 1B), as well as conserved tyrosine residues towards the C terminus. Among these tyrosines, MEGF10 Y1030 appears to be most closely associated with the development of EMARDD in humans, as defective phosphorylation at this residue has been linked to pathogenic mutations in the gene [1, 32]. Conversely, the intracellular ITAM domain that regulates established Megf10/Drpr-I mediated functions via interaction with Syk/Shark kinases (e.g., recruitment of macrophages to wounds [33] and engulfment/phagocytosis [15, 26]) is absent in Drpr-III (Fig. 1B) and thus not likely to underlie the lethality phenotype.

Sequence analysis and previous studies [34, 35] indicate that all three fly Drpr isoforms and mammalian Megf10 contain peptide sequences that share multiple conserved features with Notch ligands. These include (i) an N-terminus signal sequence followed by an Emilin-like domain (i.e., EMI), which participates in protein-protein interactions and can potently bind Notch1 [36], (ii) a Delta-Serrate-Lagged2 (DSL)-like domain which is a hallmark of Notch ligands, (iii) multiple extracellular Epidermal Growth Factor (EGF)-like repeats, and (iv) membrane anchoring via a single type I transmembrane domain. In addition, we show that the longest fly Drpr isoform (Drpr-I) and Megf10 both harbor a 'Delta and OSM-11' (DOS)-like motif located in the proximal EGF-like domains. Although DOS is found in many canonical Notch ligands and has been proposed to cooperate with the DSL motif to activate Notch [25], it is absent from Drpr-II and Drpr-III (Fig. 6), and is thus not a likely candidate region for the overexpression lethality phenotype. Of note, divergent Notch ligands that lack the DOS motif (e.g. Dll3) have been shown to play an important role in development (i.e., in somite segmentation) [37]. We postulate that at least one of the conserved extracellular domains present in the shortest isoform Drpr-III (i.e. EMI, DSL, four EGF-like domains), plays a major role in inducing fly lethality (when overexpressed in muscle) by compromising normal interactions with protein partners.

It is well established that the Notch pathway plays a central role in myogenesis. In skeletal muscle, Notch signaling regulates satellite cell self-renewal and myoblast proliferation while inhibiting myoblast differentiation [38, 39]. Similar functions have been proposed for Megf10 in myoblasts [32, 35, 40]. Further highlighting the parallels between Megf10/Drpr and Notch is the observation that developmental processes are sensitive to gene dosage in these proteins. Either haploinsufficiency or overexpression of DSL Notch ligands (wild-type or truncated forms lacking the intracellular portion) has been shown to result in morphological abnormalities [41]. Notably in *Drosophila*, both loss-of-function and gain-of-function of the Notch ligand Serrate result in similar defects at the neuromuscular junction [42]. Interestingly, we show that mutant flies that overexpress Megf10 ubiquitously and escape lethality display a tibia/tarsus leg phenotype similar to that seen in Drpr-deficient flies (Supplementary Fig. 1). It is known that Notch and its ligands, are involved in the formation of the tibial/tarsal and tarsal joints during segmentation of the insect legs [43, 44]. Our observation raises the possibility that altered levels of Megf10/Drpr affect Notch signaling during leg morphogenesis. It is unusual, however, for a gene to be poorly tolerated in both the deficient and overexpressed states [45, 46], as we observe with *Megf10/Drpr*.

It is known that complete homozygous knockouts for many genes lead to disease phenotypes, including in *Drosophila*. Haploinsufficiency phenotypes are less common but have been reported for *Drosophila* [47]. Overexpression-induced lethality, including dominant negative effects, are also less common. For example, overexpression of eighty percent of genes in yeast is well tolerated [48, 49]. In *Drosophila*, *C. elegans* and yeast, sensitivity to overexpression has been associated with an intrinsic lack of protein structure [50], the presence of linear binding motifs, and a high number of protein-protein interactions [51]. Megf10/Drpr may possess one or more of these properties.

Of note, flies that lack all adult muscles (as a result of Mef2 knockdown) become arrested as pharate adults [52]. Mef2 is essential to myoblast fusion. We have observed however that flies that overexpress Drpr-II in the entire organism die as light pupae; we thus hypothesize that Drpr-II may impair myogenic mechanisms prior to fusion, e.g., myoblast migration and/or adhesion, which might be more deleterious to the developing organism. Alternatively, increased Drpr-II expression may affect vital non-myogenic processes at the early pupal stage.

We previously reported that RNAi-mediated knockdown of Drpr/Megf10 in twist-positive muscle precursor cells results in a muscle/motor phenotype [20], however, overexpression in these same cells was found to be well-tolerated in the current study. Twist is a transcription factor highly expressed in AMPs [53, 54], and high levels of twist maintain AMPs in the undifferentiated state. In contrast, targeting Megf10/Drpr overexpression to downstream timepoints in myogenesis corresponding to the differentiation and specification stages (using the *Mef2-Gal4* and *apterous-Gal4* drivers, respectively) is deleterious to *Drosophila*, suggesting that Megf10/Drpr expression needs to be tightly regulated during these periods for myogenesis to conclude normally. Our analysis provides novel insights into the need for temporal control of Drpr expression *in vivo*.

In parallel, we observe that *Megf10/Drpr* overexpression has different effects on the two types of striated flight muscles: the indirect flight muscles (IFMs, composed of fibrillar fibers) and the direct flight muscles (DFMs, composed of tubular fibers). These muscles share the same pool of myoblasts until the late third instar larval stage, when the progenitors are specified into the two different muscle subtypes during pupation. At this stage, the ad epithelial AMPs comprise cells that express either *Vestigial* (*Vg*, in distal myoblasts) or *Cut* (*Ct*, in proximal myoblasts), that are mutually exclusive transcription factors [55, 56]. *Vg*, a marker of the developing IFMs, induces the expression of *fringe* (*fng*), a glycosyltransferase that modifies Notch, leading to the inhibition of Notch signaling and IFM formation. *Ct* positive fibers give rise to the DFMs and do not express *fng*. During pupation, the LIM-homeodomain transcription factor *apterous* (*Ap*) is activated in *Ct* positive fibers and specifies DFM identity; *Ap* is repressed in *Vg*-positive muscle cells [55–58] (Fig. 5).

We show that transgene-induced *Megf10/Drpr* expression is well-tolerated in the developing IFM/ fibrillar fibers (using the *vestigial-Gal4* driver), but is lethal in the developing DFMs/ tubular fibers (using the *Ap-Gal4*, or *cut-Gal4*, driver). The opposite sensitivity has been described with persistent expression of Notch and twist which affects the IFMs, but not the DFMs [54]. Sensitivity of *Ap* positive cells to increased levels of *Drpr* are compatible with the results of a *Beadex* (*Bx/dLMO*) gain-of-function screen that identified *Drpr* loss-of-function (LOF) mutants as suppressors of the *Bx*-induced wing margin loss phenotype [59]. *Bx* is a LIM-domain protein that competes with *Ap* for binding to its cofactor, thus reducing *Ap* activity, which in turn leads to defective Notch signaling [59]. *Drpr* loss-of-function mutations in the *Bx* mutant background are also associated with loss of macrochaete on the fly notum, as seen with Notch gain-of-function mutations (Bejarano, 2008, Heitzler and Simpson 1991). In the developing IFM and DFM muscle fibers, we thus found that Notch and *Drpr* play divergent roles and function to delineate myoblast identity toward one muscle type or the other.

The current study shows that transgene expression of *Megf10/Drpr* using the *Notch-Gal4* driver leads to lethality (of note, the *N^{gal4}* driver is a loss-of-function allele of *N*). In addition, *Drpr* overexpression in wing cells that express the Notch ligand *Serrate* results in a distinctive wing vein phenotype (i.e., extra branching at the margin) (Fig. 7), that is also found in the setting of: (i) *Serrate* overexpression in the same cells, which is associated with cis-inhibition of Notch signaling induced by excess ligand [41]; (ii) Notch deficiency [27]; (iii) *Delta* deficiency [27, 60]; or (iv) *Hairless* overexpression in the same cells [61]. *Hairless* (*H*) is a canonical inhibitor of Notch signaling activity [62–64]. Previous studies have demonstrated that *Serrate* (*Ser*) and *Wingless* (*Wg*) act in concert transiently in the late larval wing disc epithelium to modulate Notch signaling-induced asymmetric division of AMPs, which in turn generates post mitotic myoblasts prone to differentiate [65]. Here we show that high levels of *Megf10/Drpr* in *Wg* cells induces developmental arrest at the pupal stage (Fig. 7). Of note, *Wg* in L3 wing disc cells also activates the expression of the muscle-attachment gene *stripe* (*sr*) [66], and is required to maintain the IFM marker *vestigial* (*Vg*) in selected AMPs [56]. It is likely however that fly death induced by increased levels of *Megf10/Drpr* in *Wg* cells is not due to disruption of *Wg*-mediated functions on *Sr* or *Vg*, as *Megf10/Drpr* overexpression using the *Sr-Gal4* and *Vg-Gal4* drivers did not reveal lethality

(Table 1). Notably, flies that survived genetic overexpression of Drpr-III in Wg cells displayed marked histological abnormalities in tubular muscle fibers (i.e., in the jump muscle), but not in fibrillar fibers (Fig. 8, Supplementary Fig. 2). Thus, the N, Ser and Wg subpopulations of wing disc cells which play an important role in the regulation of myogenesis are highly sensitive to aberrant levels of these proteins. The severe phenotypes observed with Drpr-II overexpression in these cells suggests that its intracellular ITIM domain (unique to this isoform) may potentiate the harmful effects induced by motifs common to all three Drpr isoforms. In aggregate, our genetic analyses suggest a spatial and temporal sensitivity to increased levels of Drpr during adult myogenesis, and that high Drpr affects Notch at a critical stage of *Drosophila* muscle development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We are particularly obliged to Mary Logan (OHSU) and Marc Freeman (OHSU) for their generous gift of the transgenic *UAS-drpr-I*, *UAS-drpr-II*, *UAS-drpr-III*, *UAS-Megf10* and *drpr* null *Drosophila* lines used in these studies. We appreciate the thoughtful comments of Alan S. Kopin, as well as the expert technical assistance of Paul Spindler and Kelsey Bittner at the Department of Pathology and Laboratory Medicine, Tufts Medical Center. The genetic analyses were carried out with Gal4 driver stocks obtained from the Bloomington Drosophila Stock Center at Indiana University (NIH P40OD018537). FlyBase databases were utilized throughout the project to design experiments and interpret results. This work was supported in part by NIH R01NS080929.

References

1. Logan CV, Lucke B, Pottinger C, Abdelhamed ZA, Parry DA, Szymanska K, Diggle CP, van Riesen A, Morgan JE, Markham G, Ellis I, Manzur AY, Markham AF, Shires M, Helliwell T, Scoto M, Hubner C, Bonthron DT, Taylor GR, Sheridan E, Muntoni F, Carr IM, Schuelke M & Johnson CA (2011) Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD), *Nature genetics*. 43, 1189–92. [PubMed: 22101682]
2. Boyden SE, Mahoney LJ, Kawahara G, Myers JA, Mitsuhashi S, Estrella EA, Duncan AR, Dey F, DeChene ET, Blasko-Goehring JM, Bonnemann CG, Darras BT, Mendell JR, Lidov HG, Nishino I, Beggs AH, Kunkel LM & Kang PB (2012) Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores, *Neurogenetics*. 13, 115–24. [PubMed: 22371254]
3. Pierson TM, Markello T, Accardi J, Wolfe L, Adams D, Sincan M, Tarazi NM, Fajardo KF, Cherukuri PF, Bajraktari I, Meilleur KG, Donkervoort S, Jain M, Hu Y, Lehky TJ, Cruz P, Mullikin JC, Bonnemann C, Gahl WA, Boerkoel CF & Tiffit CJ (2013) Novel SNP array analysis and exome sequencing detect a homozygous exon 7 deletion of MEGF10 causing early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD), *Neuromuscular disorders : NMD*. 23, 483–8. [PubMed: 23453856]
4. Figeac N, Jagla T, Aradhya R, Da Ponte JP & Jagla K (2010) *Drosophila* adult muscle precursors form a network of interconnected cells and are specified by the rhomboid-triggered EGF pathway, *Development*. 137, 1965–73. [PubMed: 20463031]
5. Maqbool T & Jagla K (2007) Genetic control of muscle development: learning from *Drosophila*, *Journal of muscle research and cell motility*. 28, 397–407. [PubMed: 18347920]
6. MacDonald JM, Beach MG, Porpiglia E, Sheehan AE, Watts RJ & Freeman MR (2006) The *Drosophila* cell corpse engulfment receptor Draper mediates glial clearance of severed axons, *Neuron*. 50, 869–81. [PubMed: 16772169]

7. Fuentes-Medel Y, Logan MA, Ashley J, Ataman B, Budnik V & Freeman MR (2009) Glia and muscle sculpt neuromuscular arbors by engulfing destabilized synaptic boutons and shed presynaptic debris, *PLoS biology*. 7, e1000184. [PubMed: 19707574]
8. Logan MA & Freeman MR (2007) The scoop on the fly brain: glial engulfment functions in *Drosophila*, *Neuron Glia Biol.* 3, 63–74. [PubMed: 18172512]
9. Logan MA, Hackett R, Doherty J, Sheehan A, Speese SD & Freeman MR (2012) Negative regulation of glial engulfment activity by Draper terminates glial responses to axon injury, *Nat Neurosci.* 15, 722–30. [PubMed: 22426252]
10. Doherty J, Logan MA, Tasdemir OE & Freeman MR (2009) Ensheathing glia function as phagocytes in the adult *Drosophila* brain, *J Neurosci.* 29, 4768–81. [PubMed: 19369546]
11. Ziegenfuss JS, Doherty J & Freeman MR (2012) Distinct molecular pathways mediate glial activation and engulfment of axonal debris after axotomy, *Nat Neurosci.* 15, 979–87. [PubMed: 22706267]
12. Freeman MR, Delrow J, Kim J, Johnson E & Doe CQ (2003) Unwrapping glial biology: Gcm target genes regulating glial development, diversification, and function, *Neuron.* 38, 567–80. [PubMed: 12765609]
13. Awasaki T, Tatsumi R, Takahashi K, Arai K, Nakanishi Y, Ueda R & Ito K (2006) Essential role of the apoptotic cell engulfment genes *draper* and *ced-6* in programmed axon pruning during *Drosophila* metamorphosis, *Neuron.* 50, 855–67. [PubMed: 16772168]
14. Wu HH, Bellmunt E, Scheib JL, Venegas V, Burkert C, Reichardt LF, Zhou Z, Farinas I & Carter BD (2009) Glial precursors clear sensory neuron corpses during development via Jedi-1, an engulfment receptor, *Nat Neurosci.* 12, 1534–41. [PubMed: 19915564]
15. Scheib JL, Sullivan CS & Carter BD (2012) Jedi-1 and MEGF10 signal engulfment of apoptotic neurons through the tyrosine kinase Syk, *J Neurosci.* 32, 13022–31. [PubMed: 22993420]
16. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, Smith SJ & Barres BA (2013) Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways, *Nature.* 504, 394–400. [PubMed: 24270812]
17. Iram T, Ramirez-Ortiz Z, Byrne MH, Coleman UA, Kingery ND, Means TK, Frenkel D & El Khoury J (2016) Megf10 Is a Receptor for C1Q That Mediates Clearance of Apoptotic Cells by Astrocytes, *J Neurosci.* 36, 5185–92. [PubMed: 27170117]
18. Musashe DT, Purice MD, Speese SD, Doherty J & Logan MA (2016) Insulin-like Signaling Promotes Glial Phagocytic Clearance of Degenerating Axons through Regulation of Draper, *Cell Rep.* 16, 1838–50. [PubMed: 27498858]
19. Etchegaray JI, Elguero EJ, Tran JA, Sinatra V, Feany MB & McCall K (2016) Defective Phagocytic Corpse Processing Results in Neurodegeneration and Can Be Rescued by TORC1 Activation, *J Neurosci.* 36, 3170–83. [PubMed: 26985028]
20. Draper I, Mahoney LJ, Mitsuhashi S, Pacak CA, Salomon RN & Kang PB (2014) Silencing of *drpr* leads to muscle and brain degeneration in adult *Drosophila*, *The American journal of pathology.* 184, 2653–61. [PubMed: 25111228]
21. Brand AH & Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes, *Development.* 118.
22. Duffy JB (2002) GAL4 system in *Drosophila*: A fly geneticist's swiss army knife, *Genesis.* 34.
23. Pezeron G, Millen K, Boukhatmi H & Bray S (2014) Notch directly regulates the cell morphogenesis genes *Reck*, *talin* and *trio* in adult muscle progenitors, *Journal of cell science.* 127, 4634–44. [PubMed: 25217625]
24. D'Souza B, Meloty-Kapella L & Weinmaster G (2010) Canonical and non-canonical Notch ligands, *Current topics in developmental biology.* 92, 73–129. [PubMed: 20816393]
25. Komatsu H, Chao MY, Larkins-Ford J, Corkins ME, Somers GA, Tucey T, Dionne HM, White JQ, Wani K, Boxem M & Hart AC (2008) OSM-11 facilitates LIN-12 Notch signaling during *Caenorhabditis elegans* vulval development, *PLoS biology.* 6, e196. [PubMed: 18700817]
26. Ziegenfuss JS, Biswas R, Avery MA, Hong K, Sheehan AE, Yeung YG, Stanley ER & Freeman MR (2008) Draper-dependent glial phagocytic activity is mediated by Src and Syk family kinase signalling, *Nature.* 453, 935–9. [PubMed: 18432193]

27. Cornell M, Evans DA, Mann R, Fostier M, Flaszka M, Monthatong M, Artavanis-Tsakonas S & Baron M (1999) The *Drosophila melanogaster* Suppressor of *deltex* gene, a regulator of the Notch receptor signaling pathway, is an E3 class ubiquitin ligase, *Genetics*. 152, 567–76. [PubMed: 10353900]
28. de Celis JF, de Celis J, Ligoxygakis P, Preiss A, Delidakis C & Bray S (1996) Functional relationships between Notch, Su(H) and the bHLH genes of the E(spl) complex: the E(spl) genes mediate only a subset of Notch activities during imaginal development, *Development*. 122, 2719–28. [PubMed: 8787746]
29. Kozopas KM & Nusse R (2002) Direct flight muscles in *Drosophila* develop from cells with characteristics of founders and depend on DWnt-2 for their correct patterning, *Dev Biol*. 243, 312–25. [PubMed: 11884040]
30. Daczewska M, Picchio L, Jagla T, Figeac N & Jagla K (2010) Muscle development and regeneration in normal and pathological conditions: learning from *Drosophila*, *Curr Pharm Des*. 16, 929–41. [PubMed: 20041821]
31. Pandey KN (2009) Functional roles of short sequence motifs in the endocytosis of membrane receptors, *Front Biosci (Landmark Ed)*. 14, 5339–60. [PubMed: 19482617]
32. Mitsuhashi S, Mitsuhashi H, Alexander MS, Sugimoto H & Kang PB (2013) Cysteine mutations cause defective tyrosine phosphorylation in MEGF10 myopathy, *FEBS letters*. 587, 2952–7. [PubMed: 23954233]
33. Evans IR, Rodrigues FS, Armitage EL & Wood W (2015) Draper/CED-1 mediates an ancient damage response to control inflammatory blood cell migration in vivo, *Curr Biol*. 25, 1606–12. [PubMed: 26028435]
34. Krivtsov AV, Rozov FN, Zinovyeva MV, Hendrikx PJ, Jiang Y, Visser JW & Belyavsky AV (2007) Jedi--a novel transmembrane protein expressed in early hematopoietic cells, *Journal of cellular biochemistry*. 101, 767–84. [PubMed: 17226770]
35. Holterman CE, Le Grand F, Kuang S, Seale P & Rudnicki MA (2007) Megf10 regulates the progression of the satellite cell myogenic program, *The Journal of cell biology*. 179, 911–22. [PubMed: 18056409]
36. Schmidt MH, Bicker F, Nikolic I, Meister J, Babuke T, Picuric S, Muller-Esterl W, Plate KH & Dikic I (2009) Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural stem cell renewal, *Nature cell biology*. 11, 873–80. [PubMed: 19503073]
37. Chapman G, Sparrow DB, Kremmer E & Dunwoodie SL (2011) Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis, *Human molecular genetics*. 20, 905–16. [PubMed: 21147753]
38. Bjornson CR, Cheung TH, Liu L, Tripathi PV, Steeper KM & Rando TA (2012) Notch signaling is necessary to maintain quiescence in adult muscle stem cells, *Stem cells*. 30, 232–42. [PubMed: 22045613]
39. Mourikis P & Tajbakhsh S (2014) Distinct contextual roles for Notch signalling in skeletal muscle stem cells, *BMC Dev Biol*. 14, 2. [PubMed: 24472470]
40. Saha M, Mitsuhashi S, Jones MD, Manko K, Reddy HM, Bruels C, Cho KA, Pacak CA, Draper I & Kang PB (2017) Consequences of MEGF10 deficiency on myoblast function and Notch1 interactions, *Human molecular genetics*.
41. Fleming RJ, Hori K, Sen A, Filloramo GV, Langer JM, Obar RA, Artavanis-Tsakonas S & Maharaj-Best AC (2013) An extracellular region of Serrate is essential for ligand-induced cis-inhibition of Notch signaling, *Development*. 140, 2039–49. [PubMed: 23571220]
42. Panchumarthi S (2010) The *Drosophila* Serrate is required for synaptic structure and function at larval neuromuscular junctions, University of Arizona, Tucson, Arizona.
43. Mirth C & Akam M (2002) Joint development in the *Drosophila* leg: cell movements and cell populations, *Dev Biol*. 246, 391–406. [PubMed: 12051824]
44. Mishra A, Agrawal N, Banerjee S, Sardesai D, Dalal JS, Bhojwani J & Sinha P (2001) Spatial regulation of DELTA expression mediates NOTCH signalling for segmentation of *Drosophila* legs, *Mech Dev*. 105, 115–27. [PubMed: 11429287]

45. Deutschbauer AM, Jaramillo DF, Proctor M, Kumm J, Hillenmeyer ME, Davis RW, Nislow C & Giaever G (2005) Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast, *Genetics*. 169, 1915–25. [PubMed: 15716499]
46. Semple JI, Vavouri T & Lehner B (2008) A simple principle concerning the robustness of protein complex activity to changes in gene expression, *BMC systems biology*. 2, 1. [PubMed: 18171472]
47. Morey M, Serras F & Corominas M (2003) Halving the selenophosphate synthetase gene dose confers hypersensitivity to oxidative stress in *Drosophila melanogaster*, *FEBS letters*. 534, 111–4. [PubMed: 12527370]
48. Gelperin DM, White MA, Wilkinson ML, Kon Y, Kung LA, Wise KJ, Lopez-Hoyo N, Jiang L, Piccirillo S, Yu H, Gerstein M, Dumont ME, Phizicky EM, Snyder M & Grayhack EJ (2005) Biochemical and genetic analysis of the yeast proteome with a movable ORF collection, *Genes & development*. 19, 2816–26. [PubMed: 16322557]
49. Sopko R, Huang D, Preston N, Chua G, Papp B, Kafadar K, Snyder M, Oliver SG, Cyert M, Hughes TR, Boone C & Andrews B (2006) Mapping pathways and phenotypes by systematic gene overexpression, *Molecular cell*. 21, 319–30. [PubMed: 16455487]
50. Russell RB & Gibson TJ (2008) A careful disorderliness in the proteome: sites for interaction and targets for future therapies, *FEBS letters*. 582, 1271–5. [PubMed: 18284921]
51. Vavouri T, Semple JI, Garcia-Verdugo R & Lehner B (2009) Intrinsic protein disorder and interaction promiscuity are widely associated with dosage sensitivity, *Cell*. 138, 198–208. [PubMed: 19596244]
52. Bryantsev AL, Baker PW, Lovato TL, Jaramillo MS & Cripps RM (2012) Differential requirements for Myocyte Enhancer Factor-2 during adult myogenesis in *Drosophila*, *Dev Biol*. 361, 191–207. [PubMed: 22008792]
53. Bate M, Rushton E & Currie DA (1991) Cells with persistent twist expression are the embryonic precursors of adult muscles in *Drosophila*, *Development*. 113, 79–89. [PubMed: 1765010]
54. Anant S, Roy S & VijayRaghavan K (1998) Twist and Notch negatively regulate adult muscle differentiation in *Drosophila*, *Development*. 125, 1361–9. [PubMed: 9502718]
55. Dobi KC, Schulman VK & Baylies MK (2015) Specification of the somatic musculature in *Drosophila*, *Wiley Interdiscip Rev Dev Biol*. 4, 357–75. [PubMed: 25728002]
56. Sudarsan V, Anant S, Guptan P, VijayRaghavan K & Skaer H (2001) Myoblast diversification and ectodermal signaling in *Drosophila*, *Dev Cell*. 1, 829–39. [PubMed: 11740944]
57. Bernard F, Dutriaux A, Silber J & Lalouette A (2006) Notch pathway repression by vestigial is required to promote indirect flight muscle differentiation in *Drosophila melanogaster*, *Dev Biol*. 295, 164–77. [PubMed: 16643882]
58. Ghazi A, Anant S & VijayRaghavan K (2000) Apterous mediates development of direct flight muscles autonomously and indirect flight muscles through epidermal cues, *Development*. 127, 5309–18. [PubMed: 11076753]
59. Bejarano F, Luque CM, Herranz H, Sorrosal G, Rafel N, Pham TT & Milan M (2008) A gain-of-function suppressor screen for genes involved in dorsal-ventral boundary formation in the *Drosophila* wing, *Genetics*. 178, 307–23. [PubMed: 18202376]
60. LeBon L, Lee TV, Sprinzak D, Jafar-Nejad H & Elowitz MB (2014) Fringe proteins modulate Notch-ligand cis and trans interactions to specify signaling states, *Elife*. 3, e02950. [PubMed: 25255098]
61. Johannes B & Preiss A (2002) Wing vein formation in *Drosophila melanogaster*: hairless is involved in the cross-talk between Notch and EGF signaling pathways, *Mech Dev*. 115, 3–14. [PubMed: 12049762]
62. Bang AG & Posakony JW (1992) The *Drosophila* gene Hairless encodes a novel basic protein that controls alternative cell fates in adult sensory organ development, *Genes & development*. 6, 1752–69. [PubMed: 1516831]
63. Maier D, Stumm G, Kuhn K & Preiss A (1992) Hairless, a *Drosophila* gene involved in neural development, encodes a novel, serine rich protein, *Mech Dev*. 38, 143–56. [PubMed: 1419850]
64. Brou C, Logeat F, Lecourtois M, Vandekerckhove J, Kourilsky P, Schweisguth F & Israel A (1994) Inhibition of the DNA-binding activity of *Drosophila* suppressor of hairless and of its human

- homolog, KBF2/RBP-J kappa, by direct protein-protein interaction with *Drosophila* hairless, *Genes & development*. 8, 2491–503. [PubMed: 7958912]
65. Gunage RD, Reichert H & VijayRaghavan K (2014) Identification of a new stem cell population that generates *Drosophila* flight muscles, *Elife*. 3.
66. Ghazi A, Paul L & VijayRaghavan K (2003) Prepattern genes and signaling molecules regulate stripe expression to specify *Drosophila* flight muscle attachment sites, *Mech Dev*. 120, 519–28. [PubMed: 12782269]
67. Ni JQ, Liu LP, Binari R, Hardy R, Shim HS, Cavallaro A, Booker M, Pfeiffer BD, Markstein M, Wang H, Villalta C, Laverty TR, Perkins LA & Perrimon N (2009) A *Drosophila* resource of transgenic RNAi lines for neurogenetics, *Genetics*. 182, 1089–100. [PubMed: 19487563]
68. de Jong S, Cavallo JA, Rios CD, Dworak HA & Sink H (2005) Target recognition and synaptogenesis by motor axons: responses to the sidestep protein, *International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience*. 23, 397–410. [PubMed: 15927764]
69. Sink H, Rehm EJ, Richstone L, Bulls YM & Goodman CS (2001) sidestep encodes a target-derived attractant essential for motor axon guidance in *Drosophila*, *Cell*. 105, 57–67. [PubMed: 11301002]
70. Hatfield I, Harvey I, Yates ER, Redd JR, Reiter LT & Bridges D (2015) The role of TORC1 in muscle development in *Drosophila*, *Scientific reports*. 5, 9676. [PubMed: 25866192]
71. Weitkunat M & Schnorrer F (2014) A guide to study *Drosophila* muscle biology, *Methods*. 68, 2–14. [PubMed: 24625467]
72. Bernard F, Lalouette A, Gullaud M, Jeantet AY, Cossard R, Zider A, Ferveur JF & Silber J (2003) Control of apterous by vestigial drives indirect flight muscle development in *Drosophila*, *Dev Biol*. 260, 391–403. [PubMed: 12921740]
73. Jack J, Dorsett D, Delotto Y & Liu S (1991) Expression of the cut locus in the *Drosophila* wing margin is required for cell type specification and is regulated by a distant enhancer, *Development*. 113, 735–47. [PubMed: 1821846]
74. Simmonds AJ, Brook WJ, Cohen SM & Bell JB (1995) Distinguishable functions for engrailed and invected in anterior-posterior patterning in the *Drosophila* wing, *Nature*. 376, 424–7. [PubMed: 7630417]
75. Seroude L, Brummel T, Kapahi P & Benzer S (2002) Spatio-temporal analysis of gene expression during aging in *Drosophila melanogaster*, *Aging cell*. 1, 47–56. [PubMed: 12882353]
76. Wolf MJ & Rockman HA (2011) *Drosophila*, genetic screens, and cardiac function, *Circulation research*. 109, 794–806. [PubMed: 21921272]
77. Luan H, Peabody NC, Vinson CR & White BH (2006) Refined spatial manipulation of neuronal function by combinatorial restriction of transgene expression, *Neuron*. 52, 425–36. [PubMed: 17088209]
78. Sanyal S (2009) Genomic mapping and expression patterns of C380, OK6 and D42 enhancer trap lines in the larval nervous system of *Drosophila*, *Gene expression patterns : GEP*. 9, 371–80. [PubMed: 19602393]
79. Halter DA, Urban J, Rickert C, Ner SS, Ito K, Travers AA & Technau GM (1995) The homeobox gene repo is required for the differentiation and maintenance of glia function in the embryonic nervous system of *Drosophila melanogaster*, *Development*. 121, 317–32. [PubMed: 7768175]
80. Green RB, Hatini V, Johansen KA, Liu XJ & Lengyel JA (2002) Drumstick is a zinc finger protein that antagonizes Lines to control patterning and morphogenesis of the *Drosophila* hindgut, *Development*. 129, 3645–56. [PubMed: 12117814]
81. Cherbas L, Hu X, Zhimulev I, Belyaeva E & Cherbas P (2003) EcR isoforms in *Drosophila*: testing tissue-specific requirements by targeted blockade and rescue, *Development*. 130, 271–84. [PubMed: 12466195]
82. Fleming RJ, Gu Y & Hukriede NA (1997) Serrate-mediated activation of Notch is specifically blocked by the product of the gene fringe in the dorsal compartment of the *Drosophila* wing imaginal disc, *Development*. 124, 2973–81. [PubMed: 9247339]
83. Baumgardt M, Miguel-Aliaga I, Karlsson D, Ekman H & Thor S (2007) Specification of neuronal identities by feedforward combinatorial coding, *PLoS biology*. 5, e37. [PubMed: 17298176]

84. Perez-Garijo A, Martin FA & Morata G (2004) Caspase inhibition during apoptosis causes abnormal signalling and developmental aberrations in *Drosophila*, *Development*. 131, 5591–8. [PubMed: 15496444]


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

A



B




Figure 1. Ubiquitous overexpression of mouse Megf10, or fly Drpr, in Drosophila is harmful to the developing organism.

(A) Ubiquitous overexpression of mouse Megf10, or of the fly Drpr isoforms -I, or -III, results in pre-adult lethality. The *Act5C-Gal4* driver line was utilized to drive expression in the entire organism (the *actin5C* gene encodes a cytoskeletal actin). The corresponding experimental progeny is labeled Act5CG4>Megf10, Act5CG4>Drpr-I, Act5CG4>Drpr-III (abbreviated genotypes: *Act5C-Gal4/UAS-Megf10*, *Act5C-Gal4/UAS-drpr-I*, *Act5C-Gal4/UAS-drpr-III*, respectively). Control siblings that do not express the *Megf10*, or *drpr*, transgene (i.e., do not carry the *Gal4* transgene, abbreviated genotypes: *UAS-Megf10/CyO*, *UAS-drpr-I/CyO* and *UAS-drpr-III/CyO*, respectively), and emerge in the same cross, define the 100% expected progeny. Equal numbers of control siblings and experimental progeny is expected when the flies develop normally. The control cross was set up using *w¹¹¹⁸* (*w*) genetic background fly line x the *Act5C-Gal4* driver line. Two different progeny are

expected from this cross: $w^{1118};Act5C-Gal4$ (which do not carry the *UAS* transgene), and $w^{1118};CyO$ siblings. All progeny was generated at 29°C. Data are expressed as means +S.D. of seven data points (control cross) and two data points (each overexpression cross); each data point/cross generates 14 to 53 viable adult flies. Similar results were obtained with crosses generated at 25°C (not shown). The lethality phenotype was also observed with ubiquitous overexpression of Drpr isoform-II ($Act5C>Drpr-II$, not shown). Statistical significance, percent experimental progeny vs. control siblings, ns, not significant; *** $p < 0.001$ (paired t-test and 2-way ANOVA, GraphPad, respectively). (B) Drpr isoforms I, II and III share a subset of molecular domains (structures are based on [12]). Notably, overexpression of the shortest Drpr-III isoform is sufficient to induce lethality. Abbreviations: DSL, Delta/Serrate/LAG-2-like domain; EGF-like domain, Epidermal Growth Factor-like domain; TMD, transmembrane domain; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based inhibition motif.





Figure 2. Drosophila that overexpress Meg10/Drpr ubiquitously become arrested late in development.

(A) *Act5CG4>Megf10* progeny (abbreviated genotype *UAS-Megf10;Act5C-Gal4*) develop normally along with control siblings until the pupal stage, where the *ActCG4>Megf10* flies become arrested. The control progeny (displaying a short and rounded body due to expression of the Tubby/Tb marker, abbreviated genotype *UAS-Megf10; Tb*) eclose, leaving behind empty pupal cases, while arrested *Act5CG4>Megf10* flies remain in their pupal cases. Comparable results are obtained with Drpr-I, Drpr-II and Drpr-III. (B) Graphs showing quantification of *Megf10/Drpr* overexpressing pupae and adults (non-Tb) as a percent of corresponding control pupae and adults (Tb). 50% non-Tb animals and 50% Tb animals are expected to develop simultaneously, at each stage of development. While no significant difference in the number of experimental (i.e., *Megf10/Drpr* overexpressing) pupae versus control pupae is observed, the experimental flies do not eclose. Data are expressed as means +S.D. of four data points (each overexpression cross); each data point/cross generates 35 to 144 pupae/genotype, and 26 to 90 control adult flies. Similar results are obtained with Drpr-I (data not shown).




Figure 3. Expression of mouse Megf10 in Drosophila muscle but not in other tissues, leads to lethality.

In the assessed progeny, Megf10 is expressed under the control of the *Gal4/UAS* system which enables transgene expression in selected tissues and cell types. (A) Recapitulation of effects of targeted tissue-specific Megf10 expression on Drosophila viability (Table 1). The genetic driver utilized to test for lethality effect is indicated above each tissue. (B) Graph analysis of progeny obtained with the *D42-Gal4*, *Repo-Gal4*, *TinC-Gal4*, and *How-Gal4* driver lines, which target *UAS-Megf10* transgene expression specifically to motor neurons, glial cells, the heart, and muscle, respectively (the progeny is labeled D42G4>Megf10, RepoG4>Megf10, TinCG4>Megf10 and howG4>Megf10). Brown graphs correspond to the experimental progeny, and blue graphs correspond to control siblings (generated from the same cross and developing in the same vial, abbreviated genotypes: *CyO;D42-Gal4*, *CyO;Repo-Gal4*, *CyO;TinC-Gal4* and *CyO;how-Gal4*, respectively) that define the 100% expected progeny. Equal numbers of control siblings and experimental progeny is expected when the flies develop normally. All progeny were generated at 29°C. Data are expressed as means +S.D. of multiple data points/crosses; *D42-Gal4* *n*=4, *how-Gal4* *n*=3, *Repo-Gal4* *n*=2, and *TinC-Gal4* *n*=2; each data point/cross generates 26 to 71 viable adult flies. Similar results were obtained with crosses generated at 25°C (not shown). Statistical significance, percent experimental progeny vs. control siblings, ns, not significant; ****p* < 0.001 (paired t-test and 2-way ANOVA, GraphPad).

AHigh *twi* Inhibits differentiation*Twist*

Differentiation

Mef2

Specification

Apterous

Terminal Differentiation

Myosin heavy chain

<i>Gal4 driver</i> \ <i>UAS-cDNA</i>	Megf10	Drpr-I	Drpr-II	Drpr-III
<i>Twist</i> (AMPs)	Viable	Viable	Viable	Viable
<i>Mef2</i>	Lethal	½ Lethal	Viable	Viable
<i>Apterous</i> (muscle identity factor)	½ Lethal	Lethal	Lethal	Lethal
<i>Mhc</i> (differentiated muscles)	Viable	Viable	Viable	Viable

B

WT

Apterous-G4>Drpr-III escaper fly (wing and leg defect)

Figure 4. Overexpression of mouse Megf10 or fly Drpr at intermediate stages of myogenesis is lethal in Drosophila.

In the assessed progeny, Megf10, Drpr-I, Drpr-II or Drpr-III is expressed under the control of the *Gal4/UAS* system, which enables transgene expression at selected time points of myogenesis. (A) Overexpression of Megf10, or of Drpr, in quiescent adult muscle precursors (AMPs, that express the transcription factor *twist*), or in fully differentiated fibers (that express Myosin heavy chain, *Mhc*), does not compromise viability. Overexpression of Megf10/Drpr at intermediate steps of the myogenic process, e.g., differentiation or specification, is deleterious. 1/2 lethal = semi lethal. (B) The few flies that express Drpr-III in *apterous*-positive cells (*apterous-G4>Drpr-III*) and escape lethality display abnormalities in the wings (which remain unfolded and filled with hemolymph), as well as distorted hind legs; these flies only survive a few days (vs. a normal ~60 day-lifespan at 25°C for wild type *Drosophila*). *Apterous* is also known to express in the developing appendages [44].




Figure 5. Overexpression of Megf10/Drpr differentially affects two subtypes of developing muscle in *Drosophila* and suggests inhibition of Notch by these proteins.

(A) Top: Cartoon showing Vestigial-expressing myoblasts (magenta) vs. Cut-expressing myoblasts (green) in the pool of AMPs located in the notum of an imaginal wing disc (wild type *Drosophila*). Vestigial fibers, which develop into the indirect flight muscle (IFMs) appear insensitive to high Megf10, while Cut/Apterous fibers which develop into the direct flight muscles (DFMs) are sensitive to high Megf10. Opposite results were previously described in the literature for high Notch and Twist [54]. A postulated inhibition of Notch by Megf10/Drpr may underlie the observed effects. (B) Graphs showing the number of Megf10-expressing adult progeny obtained from parental crosses set up with either the *vestigial-Gal4*, or *cut-Gal4*, driver (two biological replicates per Gal4 driver).




Figure 6. Sequence alignment of Drosophila Drpr protein isoforms I, II and III and the homologous proteins in mouse, Megf10 and Megf12 (Jedi), shows conservation of DSL and DOS domains.

(A) top: cartoon of full-length Drpr-I. Bottom: the highest degree of similarity is found within the N-terminal EMI domain (magenta), the DSL-like domain (green), as well as in selected distal EGF-like domains (not shown). (B) The canonical DSL domain of the Notch ligands Delta (Dl, Drosophila) and Delta-like-1 (Dll1, mouse), shows significant similarity with a comparable motif found in Drosophila Drpr isoforms -I, -II, -III, mouse Megf10 and mouse Megf12 (Jedi). In addition, a DOS-like motif is found in Drpr-I, Megf10 and Jedi (residues highlighted in blue), but not in the shorter Drpr-II and Drpr-III protein isoforms. Abbreviations: DSL: Delta/Serrate/LAG-2, DOS: Delta and OSM-11.

A Effect of overexpression of fly Drpr or mouse Megf10 using drivers that target the Notch pathway.

Gal4 driver (mammalian homologous gene)	Megf10	Drpr I	Drpr II	Drpr III
Notch (Notch)	Lethal	Lethal	Lethal	Lethal
Serrate (Jagged)	split vein ¹	split vein ²	held out wings ³ and split vein ³	split vein ³
Wingless (Wnt)	Semi-lethal ⁴	Semi-lethal ⁴	Lethal	Semi-lethal ⁴

The phenotype is ¹ rare; ² semi-penetrant; ³ fully penetrant

⁴ Few escapers show markedly reduced lifespan




Figure 7. Expression of Megf10/Drpr in either Notch, Serrate or Wingless positive cells in flies leads to marked wing abnormalities, decreased motor function and/or lethality.

(A) Table summarizing the outcome of such genetic crosses using mouse Megf10 or fly Drpr homologs. (B-C) Overexpression of Drpr in Serrate positive cells results in a split (or ‘delta’) wing vein phenotype. (B) Top: normal wing from control progeny (*w*; *SerG4*). Middle: wing from progeny that express Drpr-III in serrate positive cells (*SerG4*>Drpr-III). The wing shows abnormal deltas in vein (arrows; the phenotype is 100% penetrant with Drpr-III, and mostly affects LV4 and LV5). Bottom: A similar phenotype is seen in progeny that express Drpr-III under the control of the *C179-Gal4* driver (*SerG4*>Drpr-III; Table 1). (C) Left panel: wing from progeny that express Drpr-II in serrate positive cells (*SerG4*>Drpr-II), a severe “split vein” phenotype is observed at the wing margin with LV3, LV4 and LV5. LV, Longitudinal Vein. Right panel: *SerG4*>Drpr-II progeny also display abnormally held out wings (the phenotype is 100% penetrant). (D) *SerG4*>Drpr-II flies also show marked defect in locomotor activity. 10 day-old control (*w*¹¹¹⁸; *SerG4*) and *SerG4*>Drpr II female flies were collected and functionally characterized. In each picture, the left vial contains the control flies (*n*=36), and the right vial contains the experimental flies (*n*=37). 1: the flies were prompted by taping both vials simultaneously once on a flat surface. 2, 3: the climbing ability of the flies was video recorded. Still pictures are shown. *SerG4*>Drpr II flies move markedly more slowly. The corresponding video can be accessed in the Supplementary Material. (E) Targeted expression of mouse Megf10 in wing disc cells that express Notch (using the FBst0036554 driver line) leads to lethality. The picture shows a corresponding *NG4*>Megf10 mutant fly which arrested at the late pupal/pharate adult stage, and was dissected out of the pupal case.




Figure 8. Overexpression of Drpr-III in Wg cells leads to severe abnormalities in tubular muscle fibers in adult flies.

Two day old *Wg-Gal4>UAS-drpr-III* (labeled wgG4>Drpr III) adult *Drosophila* that escaped lethality (Figure 7, Table 1), and *w¹¹¹⁸; wgG4* isogenic control flies generated in parallel, were fixed and processed for histological analysis (H&E staining). Representative longitudinal sections of fly thoraces and muscle fibers are shown. (A-B) *Wg-Gal4>UAS-drpr-III* flies. Marked abnormalities are seen in the tubular fibers that comprise the tergal depressor of the trochanter (TDT, jump muscle). The defects include marked enlargement of the fibers, hyalinization, abnormal localization/loss of nuclei, loss of striations and disruption of the characteristic bundle organization. In contrast to the tubular muscles, no gross abnormalities are detected in fibrillar fibers that comprise the large indirect flight muscles (examples are marked by asterisks at 10x magnification, as well as indicated at 40x magnification). N = 12 flies. Of note, 8 out of 12 flies where tubular fibers could be observed displayed abnormalities. Additional examples of tubular muscle defects displayed by *Wg-Gal4>UAS-drpr-III* flies are shown in Supplementary Figure 2 (from an independent replicate). (C) Age-matched *w¹¹¹⁸; wgG4* control flies show normal tubular fibers, with normal striations and well aligned central nuclei. N = 15 flies. None of the control flies showed muscle abnormalities. Magnification: 10x, 40x, as indicated. Abbreviations: D, Dorsal; V, Ventral.

Table 1.
Effect of tissue-specific overexpression of fly Drpr or mouse Megf10.

A series of GAL4 drivers was used to target transgene expression in specific tissue/cell types. Lethality is observed when using ubiquitous drivers, or selected muscle drivers. Of note, adult muscles are formed from adult muscle precursors (satellite cell-like AMPs), located on the larval wing discs.

Gal4 driver Symbol	FBstock #	Expression	Ref.	Myogenesis	Megf10	Drpr I	Drpr II	Drpr III
P(<i>Acr5C-GAL4</i>)25FO1	4414	Ubiquitous	[67]	All stages	Lethal	Lethal	Lethal	Lethal
P(<i>Acr5C-GAL4</i>)17bFO1	3954	Ubiquitous	[67]	All stages	Lethal	Lethal	Lethal	Lethal
P(<i>GAL4</i>) <i>C142</i>	64267	embryonic and larval somatic muscles [strong expression]	[68], [69]		Normal	Normal	Normal	Normal
P(<i>GawB</i>) <i>c179</i>	6450	embryonic mesoderm and larval muscles, and wing discs	[28], [70]		Lethal	Semi-lethal	Lethal	Viable ^d
P(<i>GawB</i>) <i>kirre</i> [P298-G4]	66682	Muscle progenitors and founders during early development of the mesoderm	[71]	Progenitors and founder cells	Normal	Normal	Normal	Normal
P(<i>GAL4</i> - <i>twi</i> .G)108.4	914	Embryonic and adult muscle precursors	[71]	Precursors (high twist inhibits differentiation)	Normal	Normal	Normal	Normal
P(<i>GawB</i>) <i>how</i> [24B]	1767	Mesoderm/all muscles, tendons	[71]	Early differentiation Migration/ attachment	Lethal	Lethal	Lethal	Normal
P(<i>GAL4</i> - <i>Mef2</i> .R)3	27390	All muscles	[71]	Differentiation	Lethal	Semi-lethal	Short lived ^b	Short lived ^b
P(<i>GawB</i>) <i>ap</i> [md544]	3041	Apterous cells (embryo and L1; neurons, L3; wing discs)	[72]	Identity (DFM)	Short lived ^b	Lethal	Lethal	Lethal
P(<i>cut</i> - <i>GAL4</i> .B)3	27327	Cut cells in wing discs	[73]	Identity (DFM)	Lethal	Viable ^c	Viable ^c	Viable ^c
P(<i>GAL4</i> - <i>vg</i> .M)2	6819	Vestigial cells in wing discs	[74]	Identity (IFM)	Normal	Viable ^d	Normal	Normal
P(<i>Acr88F</i> - <i>GAL4</i> .1.3)3	38459	Indirect flight muscles (IFM)	[71]	Developing IFM (after attachment) & mature IFM	Normal	Normal	Normal	Normal
P(<i>Mhc</i> - <i>GAL4</i> .F3-580)2	38464	All muscles	[71]	Differentiated muscles	Normal	Normal	Normal	Normal
P(<i>GawB</i>) <i>DJ667</i>	8171	Adult muscles (adult expression constant with age)	[75]	Differentiated muscles	Normal	Normal	Normal	Normal
P(<i>GawB</i>) <i>DJ757</i>	8184	Adult muscles (adult expression constant with age)	[75]	Differentiated muscles	Normal	Normal	Normal	Normal
P(<i>GawB</i>) <i>sr</i> [md710]	26663	Tendons	[71]	Attachment	Normal	ND	ND	Normal
<i>tirC</i> - <i>GAL4</i>	Acad.lab	Heart	[76]		Normal	Normal	Normal	Normal

Gal4 driver Symbol	FBstock #	Expression	Ref.	Myogenesis	Megf10	Drpr I	Drpr II	Drpr III
P{GMR88D05-GAL4}attP2	48396	Heart (all cardioblasts and pericardial cells), embryonic visceral muscle	[70]		Normal	Normal	Normal	Normal
P{GawB} <i>elav</i> [C155]	458	Pan neuronal	[77]		Normal	Normal	Normal	Normal
P{GawB} <i>D42</i>	8816	Motor neurons	[78]		Normal	Normal	Normal	Normal
P{GAL4} <i>repo</i>	Acad.lab.	Glia	[79]		Normal	Normal	Normal	Normal
P{ <i>dmm</i> -GAL4.7.1}1.1	7098	Intestinal tract / tubules	[80]		Normal	ND	Normal	Normal
P{ <i>Lsp2</i> -GAL4.H}3	6357	Fat body	[81]		Normal	Normal	Normal	Normal
P{GawB} N MD776 (<i>Notch-Gal4</i>)	36554	All or most cells of wing disc	<i>e</i>		Lethal	Lethal	Lethal	Lethal
P{ <i>Ser</i> -GAL4.GF}1 P{ <i>Ser</i> -GAL4.GF}2 (<i>Ser-Gal4</i>)	6791	Serrate cells in late L3 wing discs /future wing margin	[82]		Split vein	split vein	Held out wings/ split vein	split vein
P{GawB} MD758 (<i>Wg-Gal4</i>)	36525	In the pattern of the <i>wg</i> gene	[83, 84]		Semi-lethal	Semi-lethal	Lethal ^f	Semi-lethal

Normal: adult flies emerge and do not display gross abnormalities

L1: first instar larvae, L3: third instar larvae

Acad.lab.: stock obtained from an academic laboratory (details in Materials and Methods)

DFM: direct flight muscles, IFM: indirect flight muscles, ND: not determined

^a Flies display a split vein phenotype in the wing (Fig. 7)

^b Flies display reduced lifespan (~ 7 days)

^c Flies display abnormal wing epithelium and/or wing position

^d Flies show a wing phenotype as a function of age

^e Hatton-Ellis, E., Simpson, P. (<http://flybase.org/reports/FBrrf0216880.html>)

^f The lethality phenotype is recapitulated with a second *wg-Gal4* driver (i.e., P{GMR16D11-GAL4}attP2, FBst0045418), from a different laboratory (GAL4 Driver Collection of Rubin Lab at Janelia Farm, <http://flybase.org/reports/FBrrf0213040>).